Skip to main content

Table 1 Baseline demographics and disease characteristics of patients with sJIA and pcJIA (radiographic and study populations)

From: Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials

Characteristic sJIA pcJIA
Adapted SH, n = 47 Poznanski, n = 33 All, n = 112 Adapted SH, n = 45 Poznanski, n = 35 All, n = 188
Age, years 9.9 (4.3) 8.4 (4.2) 9.7 (4.6) 10.8 (3.7) 9.9 (3.3) 11.0 (4.0)
Female, n (%) 24 (51) 13 (39) 56 (50) 34 (76) 27 (77) 144 (77)
Race, white, n (%) 43 (91) 29 (88) 99 (88) 33 (73) 25 (71) 150 (80)
Body weight, kg 33.7 (15.7) 28.2 (14.5) 33.8 (19.6) 39.3 (16.3) 36.3 (14.7) 39.6 (17.3)
Disease duration, years 5.2 (4.2) 4.8 (4.1) 5.2 (4.1) 3.9 (3.3) 3.2 (2.4) 4.2 (3.7)
Joints with active arthritisa 21.3 (15.7) 19.2 (16.5) 19.8 (15.7) 20.9 (13.7) 21.7 (14.5) 20.3 (14.3)
Joints with LOMb 20.0 (15.7) 18.2 (16.7) 19.8 (15.6) 14.8 (12.0) 16.3 (13.0) 17.6 (14.4)
Patient/parent global assessment VASc 55.4 (22.7) 55.6 (25.1) 58.7 (24.4) 42.5 (26.3) 41.9 (26.4) 52.9 (25.0)
Physician global assessment VASc 62.3 (19.5) 62.8 (20.0) 64.9 (22.3) 57.2 (19.8) 59.1 (18.4) 61.4 (20.7)
CHAQ-DI score (0–3) 1.6 (0.9) 1.6 (0.9) 1.7 (0.9) 1.3 (0.6) 1.3 (0.5) 1.4 (0.7)
ESR, mm/h 53.9 (31.5) 59.2 (35.2) 57.6 (34.2) 29.9 (22.3) 30.9 (21.9) 34.8 (25.5)
Previous DMARDs use, n (%) 34 (72) 22 (67) 82 (73) 31 (69) 20 (57) 134 (71)
Previous biologic use, n (%) 39 (83) 26 (79) 92 (82) 9 (20) 7 (20) 61 (32)
Background methotrexate use, n (%) 34 (72) 28 (85) 77 (69) 39 (87) 30 (86) 148 (79)
Methotrexate dose, mg/m2/week 12.5 (3.3) 12.7 (3.3) 13.0 (5.8)
Background oral GC use, n (%) 23 (49) 12 (36) 55 (49) 19 (42) 15 (43) 86 (46)
GC dose, mg/kg/dayd 0.28 (0.17) 0.31 (0.16) 0.30 (0.20) 0.13 (0.05) 0.14 (0.05) 0.13 (0.05)
  1. Data are mean (SD) unless otherwise noted
  2. Abbreviations: CHAQ-DI Childhood Health Assessment Questionnaire–Disability Index, DMARDs disease-modifying antirheumatic drugs, ESR erythrocyte sedimentation rate, GC glucocorticoid, LOM limitation of motion, pcJIA polyarticular-course juvenile idiopathic arthritis, SD standard deviation, SH Sharp–van der Heijde, sJIA systemic juvenile idiopathic arthritis, VAS visual analog scale
  3. a71-joint count
  4. b67-joint count
  5. c0–100 mm
  6. dPrednisone equivalent